AMG 232

Drug Profile

AMG 232

Alternative Names: AMG-232

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; GlaxoSmithKline; Vanderbilt University Medical Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Acute myeloid leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 02 Feb 2017 The National Cancer Institute plans a phase I trial for Acute myeloid leukaemia (Combination therapy) in USA (PO) (NCT03041688)
  • 31 Jan 2017 The National Cancer Institute plans a phase I trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03031730)
  • 29 Nov 2016 Safety and efficacy from the phase Ib/IIa trial for Malignant melanoma presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top